MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate
Engineer and immunologist, I have spent most of my career in industry, first at Immunotech then at Innate Pharma as cofounder but also Chief Scientific Officer for nearly 14 years. Since 2012, I have brought my scientific and industrial experience to this exciting translational research tool that is MI-mAbs. Positioned at the interface of “therapeutic targets discoverers” from research and developers of the biopharmaceutical industry, MI-mAbs generates antibodies against these new targets and validates their efficacy and safety on in vivo models of human disease and in vitro, on human biological samples. MI-mAbs thus allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate.
Parallel to that mission, MI-mAbs contributes to the immunotechnology program of Master students, giving them the opportunity to learn about high precision technology such as monoclonal antibodies and their research, diagnostic or therapeutic applications. Our name – MI for Marseille Immunopole and mAbs for monoclonal antibodies – alone summarises the importance of this dual role in the cluster strategy.#industrie #recherche
The new immunotherapy antibodies currently developed by biotech companies from Marseille reflect the teams' dynamism and the extraordinary local potential.
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
AMU, IPC, CRCM